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Abstract Percutaneous MitraClip placement for treatment
of severe mitral regurgitation in high surgical risk patients is
a commonly performed procedure and requires a transseptal
puncture to reach the left atrium. The resulting iatrogenic
atrial septal defect (iASD) is not routinely closed, yet the
haemodynamic and functional consequences of a persist-
ing defect are not fully understood. Despite positive effects
such as acute left atrial pressure relief, persisting iASDs
are associated with negative consequences, namely signif-
icant bidirectional shunting and subsequent worse clinical
outcome. Percutaneous closure of the iASD may therefore
be desirable in selected cases. In this review we discuss the
available literature on this matter.
Keywords MitraClip · Iatrogenic atrial septal defect ·
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Introduction
Percutaneous mitral valve repair for the treatment of severe
mitral regurgitation has become a safe and widely used
alternative for mitral valve surgery in high-risk surgical pa-
tients [1–4]. Although repair with the MitraClip (Abbott
Vascular Structural, Menlo Park, California, USA) is less
effective at reducing mitral regurgitation (MR) compared
with conventional surgery, the procedure is associated with
superior safety and similar improvements in clinical out-
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come with respect to quality of life, heart failure status and
left ventricular function [5].
The MitraClip guiding catheter (24 French) is com-
monly introduced via the right femoral vein and requires
a transseptal puncture to access the left atrium, leaving an
iatrogenic atrial septal defect (iASD). Manipulation of the
catheter allows the system to grip the mitral valve leaflets,
subsequently effectively reducing the regurgitant orifice
([6]; Fig. 1).
A complete overview of the MitraClip procedure is de-
scribed by Feldman et al. [1]. Other percutaneous proce-
dures (7–14 French) requiring transseptal punctures, such as
pulmonary vein isolation, left atrial appendage closure, and
percutaneous balloon mitral valvuloplasty likewise result
in iASD and persistent shunting has been reported [7–9].
The haemodynamic consequences in these procedures are
thought to be minimal and therefore closure of the iASD
is not routinely performed. As iASD size increases ex-
ponentially with catheter size[10], the iASD following the
MitraClip procedure (Fig. 2) might induce haemodynami-
Fig. 1 3D atrial view (a) and 3D ventricular view (b) of MitraClip in
situ (arrows)
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Fig. 2 3D view of iatrogenic
atrial septum defect (a) and
display of shunt using colour
Doppler (b)
cally significant shunting, although little is known on this
subject.
For example, atrial septum defects with long-term left-
to-right shunting are associated with right ventricular (RV)
dilatation, ultimately leading to RV failure, pulmonary hy-
pertension, and arrhythmias [11–14]. In this review we
discuss the aspects of the iASD after MitraClip placement
and focus on 1) the prevalence, 2) haemodynamic conse-
quences, 3) case report publications, and finally 4) individ-
ual risk assessment.
A PubMed search was performed on 12 May 2016, iden-
tifying studies related to iASD following MitraClip therapy.
Search terms used were: ((atrial septal defect) OR ASD
OR (septal defect)) AND (mitraclip OR (mitral clipping)
OR (mitral valve clips) OR (mitral valve repair) OR (mitral
repair)). The search yielded 869 hits. We included rele-
vant case reports, articles reporting on the prevalence of
iASD following the MitraClip procedure, and articles dis-
cussing haemodynamic consequences of the iASD. After
cross-checking references we found four papers reporting
on the prevalence[13, 15–17], four papers assessing the
haemodynamic consequences[13, 15, 16, 18], and four pa-
pers reporting on a total of seven case reports [16, 19–21].
Prevalence
The prevalence of the iASD has been investigated in several
studies (Table 1).
Smith et al. reported a 1-month prevalence of 43% (av-
erage diameter 6.0 mm ± 2.3 mm), and 27% (6.6 mm ±
3.1 mm) at 12 months, identified using colour flow Doppler
in the apical four chamber or subcostal view on transtho-
racic echocardiography (TTE) [15]. Ussia et al. (TTE) and
Saitoh et al. (transoesophageal echocardiography (TEE))
recorded a significantly higher prevalence of 81% (average
diameter 4.5 mm ± 3.1 mm) and 82%, respectively, after
one month while Schueler et al. observed a 50% prevalence
using TEE and colour Doppler at 6 months with a maxi-
mal diameter of 4.3 mm ± 1.7 mm and minimal diameter of
3.8 mm ± 2.1 mm [13, 16, 17].
Various studies have reported on iASD prevalence fol-
lowing non-MitraClip procedures (i. e. ablation proce-
dures[7, 22–24], left atrial appendage closure [25], and
percutaneous balloon mitral valvuloplasty [9, 26–29]).
McGinty et al. grouped iASD incidence from these studies
and found an average iASD prevalence of >35% immedi-
ately following the procedure, 20% at 1–6 month follow-up,
and >10% at 6 months [30]. A direct correlation between
catheter size, iASD diameter, and prevalence[10, 16] may
explain the higher iASD prevalence following MitraClip
placement compared with non-MitraClip procedures.
Predisposing factors for the long-term prevalence of
iASDs have been suggested and include residual high trans-
mitral gradient, left ventricular (LV) hypertrophy, increased
left atrial (LA) pressure from residual MR (MR grade 2.7 ±
1.1 for iASD versus 1.5 ± 0.9 for non-iASD)[15], dura-
tion of the procedure[7, 15, 16, 27], and mitral valve
calcification [9, 28].
Haemodynamic consequences
We identified four studies assessing haemodynamic and
functional consequences of the iASD following MitraClip
placement (Table 2).
Hoffman et al. included 28 high-risk or inoperable pa-
tients with symptomatic mitral regurgitation [18]. TEE was
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Table 1 Prevalence of iASD following MitraClip therapy
Study Method N Prevalence of iASD
1 month 6 months 12 months
Smith et al. 2012[15] TTE 30 43% 27% 27%
Ussia et al. 2014[16] TTE 28 81% n/a n/a
Saitoh et al. 2012[17] TEE 11 82% n/a n/a
Schueler et al. 2015[13] TEE 66 n/a 50% n/a
iASD iatrogenic atrial septal defect, TTE transthoracic echocardiography, TEE transoesopheagal echocardiography
Table 2 Haemodynamic and functional consequences of iASD
Study N Effect Conclusion
Hoffman et al. 2014[18] 28 Positive Immediate volume and pressure relief left atrium
Smith et al. 2012[15] 30 Neutral iASDs are not haemodynamically significant
Ussia et al. 2014[16] 28 Negative Three (11%) patients developed negative haemodynamic conse-
quences, requiring closure of the iASD
Schueler et al. 2015[13] 66 Negative Persistent iASDs are associated with worse clinical outcome and
increased mortality rates
iASD iatrogenic atrial septal defect
used to measure the velocity-time integral across the iASD
and the iASD area (0.19 cm2 ± 0.05) immediately follow-
ing withdrawal of the guiding catheter, which allowed the
calculation of the shunt volume (14 ± 6 ml/beat). Invasive
LA pressure measurements showed a reduction from 17 ±
8 mm Hg to 15 ± 8 mm Hg upon catheter withdrawal, con-
tributing to LV preload reduction. The authors concluded
that the iASD resulted in immediate volume and pressure
relief of the left atrium. Unless the patient suffers from pul-
monary hypertension this effect may prove to be beneficial,
although long-term effects were not assessed in this study.
Smith et al. reviewed the echocardiographic features and
predictors of iASD following MitraClip placement in 30 pa-
tients [15]. Using TTE, RV size, LA volume and tricuspid/
mitral regurgitation were quantified in both iASD and non-
iASD patients at 12-month follow-up. No significant dif-
ferences were found in right heart mid-ventricular diameter
or LA volume, although the prevalence of iASD was as-
sociated with a relatively high LA volume index (51.4 ±
14 ml) at 12 months. Compared with non-iASD patients,
there was a significantly higher average tricuspid regurgi-
tation grade (1.1 ± 0.6 for non-iASD vs. 2.1 ± 1.8 for
iASD) and persistent MR grade (1.5 ± 0.9 for non-ASD
vs. 2.7 ± 1.1 for iASD) at 12 months. In conclusion, the
authors stated that although the iASD does not appear to
be haemodynamically significant, it is associated with rel-
atively high LA pressures, suggestive of a causative role of
high LA pressures in the persistence of the iASD.
Ussia et al. assessed the iASD in 28 patients following
MitraClip repair [16]. Three patients deteriorated haemo-
dynamically, two of which immediately following the pro-
cedure, and required iASD closure after which immedi-
ate improvement occurred; these cases are described later
in this review. The authors suggested the following three
steps to be taken to aid in the early recognition of potential
iASD complications: 1) 3D-TEE assessment of iASD shape
and diameter (laceration or diameter >8 mm may impair
spontaneous closure), 2) post-procedural atrial pressure and
O2 saturation measurement through Swan-Ganz catheterisa-
tion to assess shunt significance, and 3) detection of new
supraventricular arrhythmias which may indicate haemody-
namic deterioration.
The study performed by Schueler et al. prospectively
followed 66 patients for 6 months following MitraClip im-
plantation and compared clinical outcomes between persis-
tent iASD patients (n = 33) vs. non-iASD patients (n =
33) at follow-up [13]. Apart from a slightly larger basal
(5.1 ± 0.8 cm for iASD vs. 4.6 ± 0.8 cm for non-iASD p =
0.01) and mid-ventricular (3.7 ± 0.8 cm for iASD vs. 3.3 ±
0.7 cm for non-iASD p = 0.03) RV diameter, no differences
in baseline criteria between the two groups were observed.
During follow-up, the iASD group showed worsening of
systolic pulmonary artery pressure (PAP) post clip place-
ment (+1.6 mm Hg vs. –10.9 mm Hg for non-iASD, p =
0.02) and a larger portion of patients remained within New
York Heart Association (NYHA) class >II heart failure. At
follow-up, the iASD group showed a significant reduction
in LA volume (162.5 ± 63.3 ml to 139.1 ± 47.6 ml) sugges-
tive of a positive influence of the iASD. However, the iASD
group presented with higher levels of N-terminal pro-brain
natriuretic peptide (6667.3 ± 7363.9 ng/dl vs. 4835.9 ±
6681.7 ng/dl for non-iASD, p = 0.05) and less improve-
ment in the 6-minute walk test (20.8 ± 107.4 m vs. 114.6 ±
116.4 m, p = 0.001). Furthermore, a persisting iASD was
associated with a higher all-cause mortality rate at 6 months
(16.6% vs. 3.3%, p = 0.05). The cause of death was not
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reported and numbers were relatively small, these findings
should therefore be interpreted with caution. Furthermore,
as stated by the authors, it is unknown whether a persist-
ing iASD is the cause or effect of worse clinical outcomes.
Future studies should investigate the exact mechanism be-
hind iASD persistence and subsequently analyse long-term
clinical outcomes.
Case studies
We identified four case reports describing a total of seven
patients. Huntgeburth et al. described two patients older
than 70 years with functional MR grade 4+, severely
impaired ejection fraction (30–35%), renal impairment
and pulmonary disease [19]. These initially stable pa-
tients rapidly deteriorated following successful MitraClip
placement. Echocardiographic imaging revealed a bidi-
rectional shunt, predominantly left-to-right, in the first
patient. Acute right heart failure and cardiogenic shock
prompted iASD closure with an Amplatzer device, after
which the patient showed immediate haemodynamic im-
provement. The second patient presented with impaired
LV function (left ventricular ejection fraction (LVEF) of
30%), chronic obstructive pulmonary disease, and an en-
larged right heart chamber with compression of the LV.
The patient experienced severe right-to-left shunting with
a subsequent decline in oxygen saturation in merely hours
after the procedure, which resolved after percutaneous
iASD closure. The authors highlighted the need for post-
interventional screening for relevant shunt volumes and 24-
hour availability for emergency iASD closure.
Ussia et al. described three patients with NYHA
class III/IV heart failure undergoing MitraClip place-
ment experiencing haemodynamic deterioration [16]. All
three patients showed a final MR grade reduction of at
least 2 and iASD size ranged from 0.65 to 1 cm. One
patient showed significant left-to-right shunting eventually
leading to the development of right-sided heart failure
(15 days post-procedure). The second patient presented
with severely impaired LVEF (20%) and a systolic PAP of
30 mm Hg. Following withdrawal of the catheter the pa-
tient immediately developed bronchospasm and pulmonary
hypertension with a systolic PAP of 50 mm Hg and a bidi-
rectional shunt was detected. The third patient presented
with pulmonary hypertension (systolic PAP 65 mm Hg) and
after catheter withdrawal the systolic pulmonary pressure
increased, right-sided chamber enlargement was observed
and a left-to-right shunt was detected, eventually leading
to cardiorespiratory arrest. All three cases were resolved
through percutaneous closure with either an Amplatzer or
Figulla Occluder.
Likewise, Losi et al. reported on a 54-year-old patient
with chronic heart failure (NYHA class IV), poor LVEF, in-
creased systolic PAP (70 mm Hg), and high grade functional
MR [20]. Immediately following the procedure the patient
experienced a significant drop in the partial pressure arte-
rial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio
from 160 to 80, indicative of right-to-left shunting. Closure
of the septal defect with an Amplatzer device normalised
the PaO2/FiO2 ratio to 180. The authors suggested a possi-
ble role for the PaO2/FiO2 ratio as guidance in identifying
a clinically significant shunt.
Finally, Chandraprakasam and Satpathy described the
case of a 88-year-old female with NYHA class IV heart
failure, right ventricular systolic pressure of 60 mm Hg,
and severe MR undergoing successful MitraClip placement
[21]. Following the procedure she experienced persistent
hypoxaemia (O2 saturation 85%) despite adequate end-ex-
piratory values and a FiO2 of 100%. TEE revealed a pre-
dominantly right-to-left shunt. The defect was closed with
an Amplatzer device after which the patient improved sig-
nificantly.
Although rare, these seven case reports highlight possi-
ble consequences of a persisting iASD. The need for iASD
closure, and in which patients this may be beneficial, re-
mains an important discussion. In four of these cases, right-
to-left shunting was detected, indicative of significantly el-
evated right heart pressures. Prophylactic closure of the
defect should be considered in this patient group, although
the suitability of these patients for the MitraClip procedure
may altogether be questioned.
Risk assessment
Complications related to the iASD are relatively rare and
prophylactic closure of the defect in all patients may there-
fore not be a desirable addition to clinical care. Closure of
the defect is a permanent solution and prevents any future
transseptal procedures. Furthermore, in the acute phase fol-
lowing clip implantation, the iASD may initiate left-to-right
shunting which may reduce LA pressure and LV preload,
a potentially beneficial effect. Indeed the effect of delib-
erate transcatheter creation of an intracardiac shunt has re-
cently been analysed in non-MitraClip heart failure patients.
The resulting left-to-right shunt in patients with preserved
[31] or reduced [32] LVEF showed a marked decrease in
pulmonary capillary wedge pressure in both groups and an
improvement in NYHA heart failure class and quality of
life score [32].
On the other hand, a careful selection of at risk patients
and subsequent closure of the defect in these patients may
be beneficial. Patients with marked pulmonary hyperten-
sion with right-to-left shunting are at risk of developing
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significant hypoxia and iASD closure should be considered.
Furthermore, patients with poor RV function, pulmonary
hypertension and/or significant left-to-right shunting may
profit from closure as well. Exact cut-off values for pul-
monary hypertension, RV function and left-to-right shunt-
ing volume indicating the need for iASD closure are un-
known but are of interest for future research. As suggested
by others, post-procedural haemodynamic monitoring by
right heart catheterisation, TEE assessment of shunting and
defect size[16], and transient balloon occlusion[14] may aid
in selecting these at risk patients.
Conclusion
MitraClip patients are most often high-risk surgical patients
and represent a unique and relatively vulnerable popula-
tion. Although closure of the iASD following catheter-
based interventions is not routinely performed, the possible
consequences of iASD following MitraClip therapy are still
not fully understood. Studies have reported both positive
and negative effects of iASD. Therefore, prospective stud-
ies analysing the role of iASD closure are needed to fully
understand the mechanism and impact of the iASD and to
identify patients in which closure may be beneficial.
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